TSFVIT02:	Subjects With Maximum On-treatment Systolic Blood Pressure by Category of Blood Pressure; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Systolic Blood Pressure (mmHg), n (%) 	N=53 	N=73 	N=59 	  	  	
N 	49 	69 	55 	 	 	
<90 	0 	0 	4 (7.3%) 	-7.3 (-14.1, -0.4) 	-7.3 (-14.1, -0.4) 	
≥90 to 119 	27 (55.1%) 	23 (33.3%) 	27 (49.1%) 	6.0 (-13.2, 25.2) 	-15.8 (-33.0, 1.5) 	
≥120 to 139 	17 (34.7%) 	30 (43.5%) 	18 (32.7%) 	2.0 (-16.2, 20.2) 	10.8 (-6.3, 27.8) 	
≥140 to 159 	5 (10.2%) 	12 (17.4%) 	6 (10.9%) 	-0.7 (-12.5, 11.1) 	6.5 (-5.7, 18.6) 	
≥160 to 179 	0 	4 (5.8%) 	0 	0.0 (0.0, 0.0) 	5.8 (0.3, 11.3) 	
≥180 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation. 	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.